All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 31st European Academy of Dermatology and Venereology (EADV) Congress, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Christine Bundy, Cardiff University, Cardiff, UK. We asked, What should shared decision-making look like in the management of psoriasis and psoriatic arthritis?
Bundy begins by outlining the positive trend between health outcomes and patient involvement, and then goes through the three stages of achieving shared decision-making and the importance of providing choices between balanced treatment options.
To finish, Bundy notes the need for specific research on the impact shared decision-making has on adherence in psoriasis and psoriatic arthritis.
What should shared decision-making look like in the management of psoriasis and psoriatic arthritis?
The results of a 5-year retrospective study by Persson et al. examining safety signals in UK patients treated with apremilast compared with those not treated...
During the EULAR 2022 Congress, Lars Erik Kristensen presented the results of a study investigating...
Subscribe to get the best content related to psoriasis and psoriatic arthritis delivered to your inbox